CpG DNA as mucosal adjuvant

By McCluskie M.J.   Davis H.L.  

Vaccine, Vol. 18, Iss. 3, 1999-09 ,pp. : 231-237

Elsevier

Access to resources Recommend Favorite

Development of short non-CpG phosphodiester oligonucleotides as immune stimulatory agents

By Filion M.C.   Saha N.   Gueddi M.   Phillips N.C.  

Vaccine, Vol. 21, Iss. 9, 2003-02 ,pp. : 983-989

Elsevier

Access to resources Recommend Favorite

Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines

By Joseph A.   Louria-Hayon I.   Plis-Finarov A.   Zeira E.   Zakay-Rones Z.   Raz E.   Hayashi T.   Takabayashi K.   Barenholz Y.   Kedar E.  

Vaccine, Vol. 20, Iss. 27, 2002-09 ,pp. : 3342-3354

Elsevier

Access to resources Recommend Favorite

Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine

By Kojima Y.   Xin K.-Q.   Ooki T.   Hamajima K.   Oikawa T.   Shinoda K.   Ozaki T.   Hoshino Y.   Jounai N.   Nakazawa M.   Klinman D.   Okuda K.  

Vaccine, Vol. 20, Iss. 23, 2002-07 ,pp. : 2857-2865

Elsevier

Access to resources Recommend Favorite

Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy

By Yew Nelson S   Cheng Seng H  

Expert Opinion on Drug Delivery, Vol. 1, Iss. 1, 2004-11 ,pp. : 115-125

Informa Healthcare

Access to resources Recommend Favorite